VANDETANIB

VANDETANIB

Tablets

CAPRELSA (Vandetanib) tablets for daily oral administration are available in two dosage strengths containing either 100 mg or 300 mg of vandetanib. The tablet cores contain the following inactive ingredients: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate. The tablet film-coat contains the following inactive ingredients: hypromellose 2910, macrogol 300, and titanium dioxide E171.
Capsules: 40 mg.
300 mg once daily *CAPRELSA may be taken with or without food. Dosage reduction may be necessary in the event of severe toxicities or QTc interval prolongation. *The starting dose is 200 mg in patients with moderate to severe renal impairment.
CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease